Medicinova Inc (MNOV) Unusual Options Activity Today

Checking MNOV unusual options activity helps you spot when traders are making outsized bets on Medicinova Inc before the broader market catches on. Medicinova Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor MNOV unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching MNOV unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking MNOV unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and MNOV unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.

The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Catalysts rarely arrive without a footprint, and MNOV unusual options activity is often where that footprint shows up first. Our scanner tracks Medicinova Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at MNOV unusual options volume on the call side or chasing put sweeps, Medicinova Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.